Ultrasound-guided transvaginal radiofrequency ablation of uterine fibroids assisted by virtual needle tracking system: a preliminary study

Giovanni Turtulici, Davide Orlandi, Giorgia Dedone, Giovanni Mauri, Alessandro Fasciani, Rodolfo Sirito, Enzo Silvestri

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Purpose: The purpose of this study was to assess the feasibility and outcome of transvaginal ultrasound (US)-guided radiofrequency ablation of uterine fibroids assisted by a real-time virtual needle tracking (VT) system. Methods: Between January 2017 and February 2018, 19 patients (age 45 ± 8 y, range 36–53 y) with 25 symptomatic uterine fibroids underwent transvaginal radiofrequency ablation (RFA) at a single center. Mean number of fibroids for patient was 1.7 (min, max: 1–3). Patients with more than one fibroid were 10 (52.6%). Uterine fibroids (mean volume: 13.6 mL; range: 5.3–41.9 mL) were treated with a dedicated internally cooled 17 G 35 cm RF needle with 1 cm or variable active tip and the moving shot technique. An electromagnetic system was used for showing a virtual needle during the procedure. Contrast-enhanced ultrasound evaluation was performed before and immediately at the end of procedure. Feasibility of the procedure, technical success rate, volume percentage reduction at 1, 3 and 6 months, clinical outcome (QOL score) and complications were analyzed. Results: Procedure was feasible in 19/19 patients (100%). Technical success was achieved in 100% of 25 treated fibroids. Mean fibroids volume decreased from 13.6 ml at baseline to 5.9 ml at 6 month (reduction rate 62.7%, range 48.5–76.9; p < .05). No major immediate or late complications occurred. Minor complications occurred in two patients. QOL score significantly improved from 68 ± 36 at baseline to 97 ± 16 at six-months follow-up (p < .05). Conclusion: Transvaginal US-guided RFA assisted by a real-time VT system is a feasible, safe and effective technique for the treatment of uterine fibroids.

Original languageEnglish
Pages (from-to)1-8
Number of pages8
JournalInternational Journal of Hyperthermia
DOIs
Publication statusAccepted/In press - Jun 15 2018

Fingerprint

Leiomyoma
Needles
Electromagnetic Phenomena

Keywords

  • minimally invasive surgery
  • radiofrequency ablation
  • transvaginal myolysis
  • Uterine fibroid
  • virtual needle tracking

ASJC Scopus subject areas

  • Physiology
  • Physiology (medical)
  • Cancer Research

Cite this

Ultrasound-guided transvaginal radiofrequency ablation of uterine fibroids assisted by virtual needle tracking system : a preliminary study. / Turtulici, Giovanni; Orlandi, Davide; Dedone, Giorgia; Mauri, Giovanni; Fasciani, Alessandro; Sirito, Rodolfo; Silvestri, Enzo.

In: International Journal of Hyperthermia, 15.06.2018, p. 1-8.

Research output: Contribution to journalArticle

Turtulici, Giovanni ; Orlandi, Davide ; Dedone, Giorgia ; Mauri, Giovanni ; Fasciani, Alessandro ; Sirito, Rodolfo ; Silvestri, Enzo. / Ultrasound-guided transvaginal radiofrequency ablation of uterine fibroids assisted by virtual needle tracking system : a preliminary study. In: International Journal of Hyperthermia. 2018 ; pp. 1-8.
@article{cc33a7de05b3458a989c4d2c1573f010,
title = "Ultrasound-guided transvaginal radiofrequency ablation of uterine fibroids assisted by virtual needle tracking system: a preliminary study",
abstract = "Purpose: The purpose of this study was to assess the feasibility and outcome of transvaginal ultrasound (US)-guided radiofrequency ablation of uterine fibroids assisted by a real-time virtual needle tracking (VT) system. Methods: Between January 2017 and February 2018, 19 patients (age 45 ± 8 y, range 36–53 y) with 25 symptomatic uterine fibroids underwent transvaginal radiofrequency ablation (RFA) at a single center. Mean number of fibroids for patient was 1.7 (min, max: 1–3). Patients with more than one fibroid were 10 (52.6{\%}). Uterine fibroids (mean volume: 13.6 mL; range: 5.3–41.9 mL) were treated with a dedicated internally cooled 17 G 35 cm RF needle with 1 cm or variable active tip and the moving shot technique. An electromagnetic system was used for showing a virtual needle during the procedure. Contrast-enhanced ultrasound evaluation was performed before and immediately at the end of procedure. Feasibility of the procedure, technical success rate, volume percentage reduction at 1, 3 and 6 months, clinical outcome (QOL score) and complications were analyzed. Results: Procedure was feasible in 19/19 patients (100{\%}). Technical success was achieved in 100{\%} of 25 treated fibroids. Mean fibroids volume decreased from 13.6 ml at baseline to 5.9 ml at 6 month (reduction rate 62.7{\%}, range 48.5–76.9; p < .05). No major immediate or late complications occurred. Minor complications occurred in two patients. QOL score significantly improved from 68 ± 36 at baseline to 97 ± 16 at six-months follow-up (p < .05). Conclusion: Transvaginal US-guided RFA assisted by a real-time VT system is a feasible, safe and effective technique for the treatment of uterine fibroids.",
keywords = "minimally invasive surgery, radiofrequency ablation, transvaginal myolysis, Uterine fibroid, virtual needle tracking",
author = "Giovanni Turtulici and Davide Orlandi and Giorgia Dedone and Giovanni Mauri and Alessandro Fasciani and Rodolfo Sirito and Enzo Silvestri",
year = "2018",
month = "6",
day = "15",
doi = "10.1080/02656736.2018.1479778",
language = "English",
pages = "1--8",
journal = "International Journal of Hyperthermia",
issn = "0265-6736",
publisher = "ROUTLEDGE JOURNALS, TAYLOR FRANCIS LTD",

}

TY - JOUR

T1 - Ultrasound-guided transvaginal radiofrequency ablation of uterine fibroids assisted by virtual needle tracking system

T2 - a preliminary study

AU - Turtulici, Giovanni

AU - Orlandi, Davide

AU - Dedone, Giorgia

AU - Mauri, Giovanni

AU - Fasciani, Alessandro

AU - Sirito, Rodolfo

AU - Silvestri, Enzo

PY - 2018/6/15

Y1 - 2018/6/15

N2 - Purpose: The purpose of this study was to assess the feasibility and outcome of transvaginal ultrasound (US)-guided radiofrequency ablation of uterine fibroids assisted by a real-time virtual needle tracking (VT) system. Methods: Between January 2017 and February 2018, 19 patients (age 45 ± 8 y, range 36–53 y) with 25 symptomatic uterine fibroids underwent transvaginal radiofrequency ablation (RFA) at a single center. Mean number of fibroids for patient was 1.7 (min, max: 1–3). Patients with more than one fibroid were 10 (52.6%). Uterine fibroids (mean volume: 13.6 mL; range: 5.3–41.9 mL) were treated with a dedicated internally cooled 17 G 35 cm RF needle with 1 cm or variable active tip and the moving shot technique. An electromagnetic system was used for showing a virtual needle during the procedure. Contrast-enhanced ultrasound evaluation was performed before and immediately at the end of procedure. Feasibility of the procedure, technical success rate, volume percentage reduction at 1, 3 and 6 months, clinical outcome (QOL score) and complications were analyzed. Results: Procedure was feasible in 19/19 patients (100%). Technical success was achieved in 100% of 25 treated fibroids. Mean fibroids volume decreased from 13.6 ml at baseline to 5.9 ml at 6 month (reduction rate 62.7%, range 48.5–76.9; p < .05). No major immediate or late complications occurred. Minor complications occurred in two patients. QOL score significantly improved from 68 ± 36 at baseline to 97 ± 16 at six-months follow-up (p < .05). Conclusion: Transvaginal US-guided RFA assisted by a real-time VT system is a feasible, safe and effective technique for the treatment of uterine fibroids.

AB - Purpose: The purpose of this study was to assess the feasibility and outcome of transvaginal ultrasound (US)-guided radiofrequency ablation of uterine fibroids assisted by a real-time virtual needle tracking (VT) system. Methods: Between January 2017 and February 2018, 19 patients (age 45 ± 8 y, range 36–53 y) with 25 symptomatic uterine fibroids underwent transvaginal radiofrequency ablation (RFA) at a single center. Mean number of fibroids for patient was 1.7 (min, max: 1–3). Patients with more than one fibroid were 10 (52.6%). Uterine fibroids (mean volume: 13.6 mL; range: 5.3–41.9 mL) were treated with a dedicated internally cooled 17 G 35 cm RF needle with 1 cm or variable active tip and the moving shot technique. An electromagnetic system was used for showing a virtual needle during the procedure. Contrast-enhanced ultrasound evaluation was performed before and immediately at the end of procedure. Feasibility of the procedure, technical success rate, volume percentage reduction at 1, 3 and 6 months, clinical outcome (QOL score) and complications were analyzed. Results: Procedure was feasible in 19/19 patients (100%). Technical success was achieved in 100% of 25 treated fibroids. Mean fibroids volume decreased from 13.6 ml at baseline to 5.9 ml at 6 month (reduction rate 62.7%, range 48.5–76.9; p < .05). No major immediate or late complications occurred. Minor complications occurred in two patients. QOL score significantly improved from 68 ± 36 at baseline to 97 ± 16 at six-months follow-up (p < .05). Conclusion: Transvaginal US-guided RFA assisted by a real-time VT system is a feasible, safe and effective technique for the treatment of uterine fibroids.

KW - minimally invasive surgery

KW - radiofrequency ablation

KW - transvaginal myolysis

KW - Uterine fibroid

KW - virtual needle tracking

UR - http://www.scopus.com/inward/record.url?scp=85049926673&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85049926673&partnerID=8YFLogxK

U2 - 10.1080/02656736.2018.1479778

DO - 10.1080/02656736.2018.1479778

M3 - Article

C2 - 30012030

AN - SCOPUS:85049926673

SP - 1

EP - 8

JO - International Journal of Hyperthermia

JF - International Journal of Hyperthermia

SN - 0265-6736

ER -